(lp0
S'Pluristem Therapeutics Inc Realized Volatility Hits An Inflection Point CML News - Mar 14, 2017 This is a proprietary realized volatility rating created by Capital Market Laboratories  based on a large number of data interactions for Pluristem Therapeutics Inc  . We examine the little used gem of daily stock volatility over a ...'
p1
aS'Pluristem Therapeutics Inc. MarketWatch - Nov 12, 2010 Pluristem Therapeutics Inc. NASDAQ: PSTI. GO. Set Alerts &middot; Find a Broker &middot; Join TD Ameritrade &middot; Market Index &middot; Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.'
p2
aS"Pluristem Signs Term Sheet for $30 Million Equity Investment Agreement with a ... GlobeNewswire  - Oct 25, 2016 HAIFA, Israel, Oct. 25, 2016  -- Pluristem Therapeutics Inc. , a leading developer of placenta-based cell therapy products, today announced it has signed a term sheet for an investment of approximately&nbsp;...Israel's Pluristem to get $30m Chinese investment - The Times of Israel"
p3
aS"Exclusive Interview With Pluristem Therapeutics Inc. President ... Market Exclusive - Nov 29, 2016 I was appointed Pluristem's President and Chief Operating Officer in 2014. Prior to that, I served as Pluristem's Chief Financial Officer and Secretary since 2006, and Executive Vice President since 2013. Before joining Pluristem, I was the Chief ..."
p4
aS'Pluristem Therapeutics - A Potential Beneficiary Of The 21st Century Cures Act Seeking Alpha - Dec 16, 2016 An accelerated development time frame is obviously huge news for a company like Pluristem since it greatly reduces the amount of cash burn required  and provides a leg-up on competition.'
p5
aS'Will Pluristem Therapeutics Inc.  Succeed in CLI Where Sanofi SA ... Market Exclusive - Aug 11, 2016 Pluristem Therapeutics Inc.  has achieved just that, hitting for the cycle so to speak, with two accelerated approval pathways for its PLX-PAD placental cell treatment for critical limb ischemia .'
p6
aS'FBR Capital Analyst Bullish on Pluristem Therapeutics Inc.  Following ... Smarter Analyst - Jul 11, 2016 FBR Capital analyst Vernon Bernardino weighed in on Pluristem Therapeutics Inc.  following the an announcement that the company plans to initiate a Phase I trial to investigate its PLX-R18 drug.'
p7
aS'Pluristem Announces Bought Deal Offering GlobeNewswire  - Jan 19, 2017 HAIFA, Israel, Jan. 19, 2017  -- Pluristem Therapeutics Inc.   announced today that it has entered into an underwriting agreement with H.C.Pluristem Therapeutics  Increases Bought Deal Offering of Common Stock ... - StreetInsider.comMaxim Group Reiterates $3.00 Price Target for Pluristem Therapeutics Inc.  - The Cerbat Gem'
p8
aS'Pluristem Therapeutics Inc.: Pluristem Reports Second Quarter Fiscal 2017 ... The Wall Street Transcript - Feb 13, 2017 HAIFA, Israel, February 13, 2017 -- Pluristem Therapeutics Inc. , a leading developer of placenta-based cell therapy products, today reported financial update and corporate and clinical developments for the second quarter of ...Pluristem Reports Second Quarter Fiscal 2017 Highlights &amp; Provides Calendar ... - GlobeNewswire Pluristem Therapeutics  is Downgraded by Maxim Group to  Hold - Highland Mirror'
p9
aS'Pluristem Therapeutics: Questionable Ethics And Bucket Shop Coverage Seeking Alpha  - Feb 2, 2015 Pluristem Therapeutics Inc.  is a clinical-stage company engaged in development of cell therapy products for the treatment of life threatening diseases.'
p10
a.